Nijmegen, August 19th, 2024 – TropIQ Health Sciences is pleased to announce the appointment of Michiel van Alst as the new Chief Executive Officer, effective September 1st, 2024….

Recently, our inhibition of liver stage development assay, as well as assays on the sexual parasite stages contributed to the publications of two new articles. Read more here…

We contributed to a paper on a newly generated reporter line expressing NanoLuciferase. Within two weeks another paper we collaborated on came out about blocking transmission of gametocytes….

In a collaboration with Google Research and Osmo, TropIQ contributed to a landmark paper that provides fundamental insights into the relationship between odors. It demonstrates that perceptual similarity…

We investigated how susceptible the early stages of malaria are to chemical treatments, and we created a screening strategy to identify new drugs that can prevent infection. The results are…

TropIQ contributed to two studies that identified novel malaria transmission-blocking monoclonal antibodies from naturally exposed individuals. These studies are published in Immunity. Read more here and here.

TropIQ assessed drug sensitivity of a new genetically attenuated malaria parasite that qualifies as a vaccine candidate. The results of these studies have been now been published in…

  Together with researchers from the University of Washington, TropIQ was awarded 1.3 million USD from the Bill & Melinda Gates Foundation to find new mosquito repellents and…

The Malaria Drug Accelerator (MalDA), of which TropIQ is part of, has put together a prioritisation of molecular targets against the malaria parasite Plasmodium falciparum. This publication further…

Due to the continuing rise of resistances against commonly used medication, new anit-malarials are needed to combat the disease. This publication suggests Quinazolinone-2-carboxamide derivatives as a novel malaria…

TropQI has been a part of The Malaria Drug Accelerator (MalDA) since 2018. This consortium consists of 17 research laboratories funded by the Bill and Melinda Gates foundation…

In the battle against malaria new drugs are needed. This publication identified 1-(pyridine-4-yl)pyrrolidine-2-one derivates as a novel, dual stage active (asexual blood stages and liver stage), anti-malaria. read…

To broaden the protective spectrum of a potential whole parasite vaccine against malaria, a chimeric P. falciparum parasite expressing P. falciparum and P. vivax circumsporozoite protein (csp) was…

Production of the primary vaccine candidate Plasmodium falciparum circumsporozoite protein (PfCSP) has proven difficult. This publication for the first time presents a method to produce a soluble, full-length…

Dutch national radio (BNR) has conducted an interview with TropIQ’s CEO Koen Dechering on the recently published novel malaria drug candidate (see publication here). Listen to the interview…

A molecule once designed to cure the skin disease psoriasis appears to be particularly effective against malaria. The antimalarial properties were revealed thanks to one researcher’s inspired hunch…

TropIQ organised a science workshop at the IMC Weekend School. This is a supplementary school on Sundays for children (aged 10-14) from underprivileged neighbourhoods. Through a three-year course,…

Robert Sauerwein, CSO of TropIQ, receives a royal decoration for his pioneering work in malaria vaccinology and drug discovery. He receives the distinction of Knight in the Order…

As a reaction to TropIQs latest study preventing transmission of tropical diseases, published in PNAS in July this year, the Dutch television program EenVandaag (NPO1) presented an item…

The scientific journal Science report on TropIQ’s finding that dog’s flea and tick medication could prevent the spread of vector borne diseases like malaria and Zika. Click here…

Time Magazine has reported on TropIQ’s finding that veterinary drugs have the potential to protect humans from malaria, Zika, and other diseases transmitted by blood feeding insects. Read…

Our research shows that, given to humans, insect killing veterinarian drugs can greatly reduce

New research, with TropIQ contribution, on a compound series active against malaria asexual and sexual stages was published today. Read more here.

Once a year malaria research groups in the Netherlands come together to share their newest results, discuss future plans and collaborative efforts. This year this event was organised…

TropIQ publishes novel modelling method for predicting the effectiveness of drugs on malaria transmission. The publication “Modelling mosquito infection at natural parasite densities

TropIQ co-authors the publication “A potent series targeting the malarial cGMP-dependent protein

The publication “Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase.” came out today.

Here the “gold standard” status for transmission blocking activity of antibodies, the standard membrane feeding assay (SMFA), is verified in two different laboratories. Read the article here.

TropIQ has moved to a brand new laboratory at the Noviotech campus in Nijmegen, The Netherlands.

Read full article here. 

TropIQ has entered a Netherlands-based consortium that teams up with MMV in world-leading malaria translational research.

TropIQ enters partnership with MMV (Medicines for Malaria Venture) on generation of a pantothenamide clinical candidate.

“A semi-automated luminescence based standard membrane feeding assay identifies novel small molecules that inhibit transmission of malaria parasites by mosquitoes” We describe here for the first time a…

TropIQ receives a Grand Challenges and Explorations award from the Bill & Melinda Gates Foundation to develop barcoded insect screens for optimization of artificial diets.

TropIQ staff co-authors the study ‘A simple and predictive phenotypic High Content Imaging assay for Plasmodium falciparum mature gametocytes to identify malaria transmission blocking compounds’ that was published by Scientific…

TropIQ employees co-author the study ‘A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria’ that was published by Science Translational Medicine today.

TropIQ contributed to the study ‘Analysis of a Multi-component Multi-stage Malaria Vaccine Candidate—Tackling the Cocktail Challenge’ that was published by Plos One today.

Nature publishes the paper ‘A novel multiple-stage antimalarial agent that inhibits protein synthesis’ that is co-authored by TropIQ.

TropIQ employees co-author the manuscript ‘Salinomycin and other ionophores as new class of antimalarial drugs with transmission blocking activity’ that appeared in Antimicrobial Agents and Chemotherapy today.

TropIQ employees co-author the manuscript Novel pantothenate derivatives for anti-malarial chemotherapy that appeared in Malaria Journal today.

Watch the full video here

In the publication “A combination of new screening assays for prioritization of transmission-blocking antimalarials

TropIQ and the California Research Institute for Biomedical Research (Calibr) enter a research collaboration. TropIQ will perform barcoded mosquito assay to support Calibr’s insecticide program.